It's NTA backed to 16c with $18M cash so enormous value here. The only problem is the lead time till first significant trial data, which will be Q1 2016, all going as planned. Should get an Ann soon on commencement. If it goes much lower than 14c I'm just going to buy and hold the opportunity cost into next year.
Bioshares 14/11/14, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)